Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biolinerx Ltd (BLRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,128
  • Shares Outstanding, K 106,490
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,350 K
  • 36-Month Beta 1.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.17
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/05/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.38 +6.58%
on 02/08/19
0.87 -53.45%
on 02/04/19
-0.20 (-32.50%)
since 01/15/19
3-Month
0.38 +6.58%
on 02/08/19
0.87 -53.45%
on 02/04/19
-0.25 (-37.88%)
since 11/15/18
52-Week
0.38 +6.58%
on 02/08/19
1.84 -77.99%
on 10/04/18
-0.61 (-59.90%)
since 02/15/18

Most Recent Stories

More News
Biotech on the Brink of Breaking Out

HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now.

FBIO : 2.18 (+0.46%)
GWPH : 150.49 (-0.53%)
BLRX : 0.41 (unch)
Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19)

CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / The market has garnered copies amounts of media attention over the course of the past few years, as more people have come to understand the variety of...

ACB : 7.05 (-0.70%)
PHGI.CN : 0.830 (unch)
CANF : 1.14 (unch)
PHGRF : 0.6316 (+1.95%)
BLRX : 0.41 (unch)
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer

BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...

BLRX : 0.41 (unch)
BioLineRx to Present at the 2019 Biotech Showcase

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that management will provide a corporate update at the 2019 Biotech...

BLNEF : 0.8600 (unch)
BLRX : 0.41 (unch)
BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the initiation of the triple combination arm of the Phase 2a COMBAT/KEYNOTE-202...

BLRX : 0.41 (unch)
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York

BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December...

BLNEF : 0.8600 (unch)
BLRX : 0.41 (unch)
BioLineRx to Report Third Quarter 2018 Results on November 8, 2018

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter...

BLRX : 0.41 (unch)
BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress

BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced top-line results from the dual combination arm of the Phase 2a...

BLRX : 0.41 (unch)
BioLineRx, High Potential Near Term Catalysts, Analysts Review and Target

NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

BLRX : 0.41 (unch)
Can The Uptrend Continue for BioLineRx (BLRX)?

Investors certainly have to be happy with BioLineRx Ltd. (BLRX) and its short term performance.

BLRX : 0.41 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade BLRX with:

Business Summary

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040,...

See More

Key Turning Points

2nd Resistance Point 0.42
1st Resistance Point 0.41
Last Price 0.41
1st Support Level 0.40
2nd Support Level 0.40

See More

52-Week High 1.84
Fibonacci 61.8% 1.28
Fibonacci 50% 1.11
Fibonacci 38.2% 0.94
Last Price 0.41
52-Week Low 0.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar